Showing results (3271-3280 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|September 19, 2003
Heparan sulphate epitope-expression is associated with the inflammatory response in metastatic malignant melanomaMonique R Bernsen, Toon F C M Smetsers, Els van de Westerlo, et al.Cancer Immunology, Immunotherapy : CII|November 20, 2021
Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cellsTrefa M Abdullah, Jacqueline Whatmore, Edwin Bremer, et al.Cancer Immunology, Immunotherapy : CII|November 24, 2021
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapyQiaoyun Tan, Liyuan Dai, Yanrong Wang, et al.Cancer Immunology, Immunotherapy : CII|March 13, 2021
Tumor immune microenvironment in brain metastases from gynecologic malignanciesCorey M Gill, Megan R D'Andrea, Shannon Tomita, et al.Cancer Immunology, Immunotherapy : CII|March 19, 2021
Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinomaChien-Hsu Chen, Mu-Yao Tsai, Ping-Chia Chiang, et al.Cancer Immunology, Immunotherapy : CII|December 2, 2021
MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cuesTony Yao, Patrick T Rudak, Céline M Laumont, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1986
Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphologyG G MacPherson, R J NorthCancer Immunology, Immunotherapy : CII|November 25, 2021
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective studyGeoffroy Bilger, Nicolas Girard, Hélène Doubre, et al.Cancer Immunology, Immunotherapy : CII|November 25, 2021
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigensGerulf Hänel, Caroline Angerer, Katja Petry, et al.Cancer Immunology, Immunotherapy : CII|November 5, 2021
Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapyChuan Liu, Guangwei Zhang, Kanghui Xiang, et al.Pageof 652